Kronos Bio, Inc. (KRON) - Quarterly EPS earnings growth

Official company branding of Kronos Bio (KRON)

Kronos Bio, Inc. (KRON) profitability is constrained by massive R&D expenditures and clinical trial risks. The quarterly earnings per share growth illustrates this trend, where the value 72.20 shows the current metric. The issuer's success depends on regulatory approval of its therapies; however, current cash flow pressure and dwindling reserves create serious financial challenges for the business.

Kronos Bio (KRON) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 06/28/2025

Analytical breakdowns for Kronos Bio, Inc.

- market value and analyst target forecast:
Price Chart Kronos Bio|KRON - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Kronos Bio Corp|KRON - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Kronos Bio|KRON - Total Stockholders' Equity|Market Value to Book Value Ratio kronosbio.com|KRON - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Kronos Bio, Inc.|KRON - Long-Term Liabilities to Capital|Short-Term Debt to Capital Kronos Bio, Inc.|KRON - Company Total Indebtedness|Debt to Book Value Kronos Bio Corp|KRON - Long-Term Debt|Company Current Liabilities Kronos Bio|Quick Liquidity Indicator kronosbio.com
- earnings and market multiples details:
KRON - Profit After Payment of Taxes|Projected Future Earnings Kronos Bio, Inc.|KRON - Company Value to Net Income|Forward P/E Multiple Kronos Bio Corp|KRON - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio Corp|KRON - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Kronos Bio|KRON - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months kronosbio.com|KRON - Earnings per share trend in current year|Expected earnings per share growth for next year Kronos Bio, Inc.
Fundamental company analysis:Kronos Bio, KRON
Manufactured product of Kronos Bio Corporation

This indicator measures the year-over-year quarterly dynamics of net income per share, allowing investors to filter out market noise and identify the actual pivot point of operational efficiency. By analyzing quarterly net income per share growth, the investor can see the results of Kronos Bio, Inc. (KRON) implementing rigorous R&D expenditure optimization and concentrating capital on its key inhibitor, KB-0742.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring, Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla, Inc.)|LIXT (Lixte Biotechnology, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (cellectar.com)|BioLineRx - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma Ltd)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kazia Therapeutics Limited (KZIA)|Year-over-year earnings per share growth for the last twelve months Silexion Therapeutics Corp.|NCNA: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CMRX|Quarterly EPS earnings growth Cyclacel Pharmaceuticals, Inc. (CYCC)|Year-over-year earnings per share growth for the last twelve months G1 Therapeutics GTHX|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com